Advertisement
AXON vs HALO
Which Stock Would AI Choose? Axon Enterprise (AXON) vs. Halozyme Therapeutics (HALO) Stock Comparison
Key Takeaways
- AXON (AXON) reported Q1 2026 revenue growth of 33.7% to $807 million, driven by AI software and international Taser demand, though shares have declined ~29% YTD amid volatility.
- HALO (HALO) achieved record 2025 revenue of $1.4 billion (up 38% YoY) with royalty revenue surging 52%, but stock is down ~5% YTD after a Q4 earnings miss.
- AXON's 1-year return lags at -41% versus S&P 500's +31%, reflecting high valuation (P/E ~162) and sector pressures; HALO's 1-year return is +5%, with lower beta (0.88) indicating relative stability.
- Recent catalysts: AXON raised full-year guidance on AI growth (up 700%); HALO secured partnerships with GSK and Oruka, reiterating strong 2026 outlook.
- Sector contrast: AXON in volatile industrials/aerospace; HALO in steadier biotech with ENHANZE platform royalties from partners like Roche and Janssen.
- Market positioning: AXON shows higher growth potential but elevated risk; HALO offers balanced profitability with forward P/E ~8.
Introduction
This comparison examines AXON and HALO amid shifting market dynamics in technology-driven industrials and biotechnology. AXON Enterprise focuses on public safety hardware and software, while Halozyme Therapeutics enables subcutaneous drug delivery via its ENHANZE platform. Traders seeking growth in AI-integrated defense or biotech royalties, and investors eyeing relative stability versus momentum, will find value in analyzing their recent performances, sector exposures, and catalysts. Both stocks highlight trade-offs between high-growth volatility and consistent royalty streams in the current environment.
AXON Overview and Recent Performance
Axon Enterprise (AXON), headquartered in Scottsdale, Arizona, develops public safety technologies including TASER conducted energy devices, body cameras, and cloud-based evidence management software. In recent quarters, the company reported Q1 2026 revenue of $807 million, up 33.7% year-over-year, fueled by 700% growth in AI revenue and rising international demand for TASER products. It raised full-year revenue guidance to 30-32% growth, citing counter-drone and software expansions. However, adjusted EPS of $1.61 slightly missed estimates, contributing to stock volatility. Shares traded around $403 recently, down approximately 29% YTD and 41% over one year from a 52-week high of $886, reflecting broader industrials pressures and tariff concerns, despite long-term outperformance (5-year return +200%). Sentiment is buoyed by AI catalysts but tempered by high valuation (P/E 162) and beta of 1.43 (higher market sensitivity).
HALO Overview and Recent Performance
Halozyme Therapeutics (HALO), based in San Diego, California, is a biopharma platform company specializing in the ENHANZE enzyme (rHuPH20) for subcutaneous drug delivery, partnering with firms like Roche, Janssen, and Pfizer. Full-year 2025 revenue hit a record $1.4 billion, up 38% YoY, with royalties jumping 52% to $868 million from blockbusters like DARZALEX SC and Phesgo. Recent developments include new collaborations with GSK and Oruka for oncology and autoimmune targets, plus approvals expanding ENHANZE reach. Q4 2025 saw an EPS miss (-$0.24 vs. expected $1.92), leading to share pressure. Trading near $64, HALO is down ~5% YTD and flat over one year (52-week range $47.50-$82.22), with 3-year returns at +112%. Lower beta (0.88) signals stability; forward P/E ~8 reflects profitability, though 3-month declines (~20%) stem from biotech sector rotation.
Trending AI Robots
Tickeron’s Trending AI Robots page features 25 top-performing AI trading bots curated from over 351 total bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like trend analysis, multi-agent systems, and TP/SL corridors on timeframes from 5 minutes to 60 minutes, targeting sectors such as semiconductors, industrials, biotech-adjacent data centers, and leveraged plays. Performance highlights include annualized returns up to +285% (e.g., space infrastructure), win rates of 70-80% or higher (up to 88%), and profit factors reaching 11.7, with examples like +167% annualized on volatility plays and 75% win rates on semiconductor baskets. Only the most suitable for current conditions—based on momentum, sector rotation, and risk-adjusted metrics—earn a spot here. Explore these bots to align with your trading style and market outlook.
Head-to-Head Comparison
AXON and HALO diverge in business models: AXON's integrated hardware-software ecosystem drives recurring SaaS revenue (majority from connected devices), contrasting HALO's royalty-focused biotech platform licensing ENHANZE to big pharma for co-formulated drugs. Growth drivers differ—AXON leverages AI enhancements and public safety budgets amid geopolitical tensions; HALO benefits from partner milestones and subcutaneous shift in oncology/immunology. Recent momentum favors neither decisively: AXON's post-earnings rebound offset YTD losses, while HALO stabilized after partnerships but faced earnings volatility. Risk profiles highlight AXON's higher beta (1.43) and tariff exposure versus HALO's lower volatility (beta 0.88) and partnership dependencies. Sector-wise, AXON ties to cyclical industrials/aerospace; HALO to defensive biotech royalties. Market sentiment leans bullish on AXON's catalysts (analyst targets ~$666-$825) but values HALO's cheaper valuation and 22-30% 2026 revenue growth projection.
Tickeron AI Verdict
Tickeron’s AI currently favors AXON due to superior trend consistency in AI-driven public safety demand, recent revenue acceleration (33.7% QoQ), and raised guidance signaling catalysts amid industrials rotation. HALO's stability and partnerships offer appeal, but AXON's relative positioning in high-momentum sectors like aerospace (aligned with trending bots) suggests higher probabilistic upside in the near term, balanced against its volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AXON is a StrongBuy and HALO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AXON’s FA Score shows that 0 FA rating(s) are green whileHALO’s FA Score has 2 green FA rating(s).
- AXON’s FA Score: 0 green, 5 red.
- HALO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AXON’s TA Score shows that 4 TA indicator(s) are bullish while HALO’s TA Score has 2 bullish TA indicator(s).
- AXON’s TA Score: 4 bullish, 6 bearish.
- HALO’s TA Score: 2 bullish, 4 bearish.
Price Growth
AXON (@Aerospace & Defense) experienced а -7.49% price change this week, while HALO (@Biotechnology) price change was -0.03% for the same time period.
The average weekly price growth across all stocks in the @Aerospace & Defense industry was -3.54%. For the same industry, the average monthly price growth was -4.48%, and the average quarterly price growth was +13.68%.
The average weekly price growth across all stocks in the @Biotechnology industry was +5.83%. For the same industry, the average monthly price growth was +1.96%, and the average quarterly price growth was +1945.11%.
Reported Earning Dates
AXON is expected to report earnings on Aug 11, 2026.
HALO is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Aerospace & Defense (-3.54% weekly)Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.
@Biotechnology (+5.83% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| AXON | HALO | AXON / HALO | |
| Capitalization | 34.9B | 8.26B | 423% |
| EBITDA | 320M | 624M | 51% |
| Gain YTD | -27.803 | 3.447 | -807% |
| P/E Ratio | 165.33 | 24.21 | 683% |
| Revenue | 2.98B | 1.51B | 198% |
| Total Cash | 737M | 319M | 231% |
| Total Debt | 1.83B | 2.15B | 85% |
AXON | HALO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 66 | 61 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 75 Overvalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 68 | 51 | |
SMR RATING 1..100 | 81 | 12 | |
PRICE GROWTH RATING 1..100 | 63 | 50 | |
P/E GROWTH RATING 1..100 | 63 | 14 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AXON's Valuation (75) in the Biotechnology industry is in the same range as HALO (83). This means that AXON’s stock grew similarly to HALO’s over the last 12 months.
HALO's Profit vs Risk Rating (51) in the Biotechnology industry is in the same range as AXON (68). This means that HALO’s stock grew similarly to AXON’s over the last 12 months.
HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for AXON (81). This means that HALO’s stock grew significantly faster than AXON’s over the last 12 months.
HALO's Price Growth Rating (50) in the Biotechnology industry is in the same range as AXON (63). This means that HALO’s stock grew similarly to AXON’s over the last 12 months.
HALO's P/E Growth Rating (14) in the Biotechnology industry is somewhat better than the same rating for AXON (63). This means that HALO’s stock grew somewhat faster than AXON’s over the last 12 months.
| AXON | HALO | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 63% | N/A |
| Stochastic ODDS (%) | 2 days ago 82% | 2 days ago 71% |
| Momentum ODDS (%) | 2 days ago 71% | 2 days ago 69% |
| MACD ODDS (%) | 2 days ago 71% | 2 days ago 63% |
| TrendWeek ODDS (%) | 2 days ago 67% | 2 days ago 66% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 75% |
| Advances ODDS (%) | 22 days ago 74% | 20 days ago 80% |
| Declines ODDS (%) | 12 days ago 69% | 6 days ago 66% |
| BollingerBands ODDS (%) | 2 days ago 69% | 2 days ago 67% |
| Aroon ODDS (%) | 2 days ago 72% | N/A |
Advertisement
AXON and
Correlation & Price change
A.I.dvisor indicates that over the last year, AXON has been loosely correlated with TECH. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if AXON jumps, then TECH could also see price increases.
| Ticker / NAME | Correlation To AXON | 1D Price Change % | ||
|---|---|---|---|---|
| AXON | 100% | -3.16% | ||
| TECH - AXON | 61% Loosely correlated | -3.97% | ||
| VCYT - AXON | 58% Loosely correlated | -0.82% | ||
| BEAM - AXON | 57% Loosely correlated | +4.07% | ||
| SEER - AXON | 56% Loosely correlated | +1.15% | ||
| ADPT - AXON | 56% Loosely correlated | -0.86% | ||
More | ||||